Cormorant Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Cormorant Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-125,000	Closed	-$19.8M	–	53
2024 Q2	$19.8M	Buy	+125,000	New	+$16.1M	1.14%	25
2023 Q3	–	Sell	-130,000	Closed	-$14.9M	–	63
2023 Q2	$14.9M	Buy	130,000 +20,000	+18%	+$2.58M	0.83%	30
2023 Q1	$15.2M	Sell	110,000 -90,000	-45%	-$11.7M	1%	27
2022 Q4	$25.9M	Hold	200,000	–	–	1.73%	18
2022 Q3	$22.1M	Buy	+200,000	New	+$20.2M	1.55%	24
2021 Q2	–	Sell	-70,000	Closed	-$5.22M	–	123
2021 Q1	$5.22M	Hold	70,000	–	–	0.12%	94
2020 Q4	$11.9M	Sell	70,000 -15,000	-18%	-$2.22M	0.28%	60
2020 Q3	$11.9M	Sell	85,000 -25,000	-23%	-$3.8M	0.46%	52
2020 Q2	$17.6M	Sell	110,000 -40,000	-27%	-$5.44M	0.67%	47
2020 Q1	$14.7M	Sell	150,000 -100,000	-40%	-$11.4M	0.68%	42
2019 Q4	$32.3M	Buy	250,000 +28,300	+13%	+$2.86M	1.29%	26
2019 Q3	$16.7M	Sell	221,700 -3,300	-1%	-$390K	1.02%	33
2019 Q2	$34.2M	Sell	225,000 -75,000	-25%	-$9.11M	1.96%	16
2019 Q1	$35.8M	Buy	300,000 +210,000	+233%	+$27M	2.42%	13
2018 Q4	$9.82M	Buy	+90,000	New	+$11.3M	0.8%	35

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cormorant Asset Management's SRPT Position: Q3 2024 in Review

Cormorant Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 125,000 shares — an estimated $19.8M sold.

Cormorant Asset Management first reported a position in SRPT in Q4 2018 and held it in 15 quarters. The position peaked at $35.8M in Q1 2019. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Cormorant Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Cormorant Asset Management sold 125,000 Sarepta Therapeutics shares in Q3 2024, an estimated $19.8M.
Cormorant Asset Management first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 15 quarters.
Cormorant Asset Management's Sarepta Therapeutics position peaked at $35.8M in Q1 2019.
458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Cormorant Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.